Core Viewpoint - Meili Tianyuan Medical Health (02373.HK) has released a positive profit forecast for the fiscal year 2025, expecting revenue of at least 3 billion yuan, a growth of no less than 16% compared to 2024, and an adjusted net profit of at least 380 million yuan, representing a year-on-year increase of no less than 40% [1][3]. Group 1: Revenue and Profit Forecast - The company anticipates a revenue of no less than 3 billion yuan for 2025, which is an increase of at least 16% from the previous year [1]. - Adjusted net profit is expected to be no less than 380 million yuan, reflecting a year-on-year growth of at least 40% [1]. - The net profit is projected to be no less than 340 million yuan, indicating a year-on-year increase of at least 34% [1]. Group 2: Factors Influencing Performance - The company attributes its performance to two main factors: external acquisitions and organic business growth [3][4]. - The acquisition of the second-largest brand in the Chinese beauty industry, Nairui'er, has expanded the company's business coverage and improved its adjusted net profit margin from 6.5% to 10.4% in the first half of 2025 [3]. - The company has also completed the acquisition of the third-largest beauty service brand, Siyuanli, further consolidating its position in the industry [3]. Group 3: Business Strategy and Future Outlook - The company is focusing on high-end female consumer groups in major cities, responding to the growing "self-indulgent consumption" demand, which has boosted same-store revenue [4]. - In November 2025, the company announced three strategic directions: "Super Brand," "Super Chain," and "Super Digitalization," aimed at exploring the high-end beauty service sector [5]. - The company plans to continue its dual-driven strategy of "organic growth + external acquisitions" and deepen its "dual beauty + dual healthcare" business model [5].

Core Viewpoint - Meili Tianyuan Medical Health Industry Co., Ltd. forecasts a positive profit outlook for 2025, expecting revenue of at least 3 billion yuan, a year-on-year increase of no less than 16%, and adjusted net profit of at least 380 million yuan, representing a growth of no less than 40% [1] Group 1: Performance Growth Drivers - The company demonstrates strong resilience and growth potential through robust performance, attributed to two main factors: accelerated external expansion and strong internal growth momentum [2][3] - The successful acquisition of the second-largest brand in the Chinese beauty industry, Nairui'er, has significantly enhanced the company's market share and business footprint in key areas, with Nairui'er’s adjusted net profit margin increasing from 6.5% to 10.4% post-acquisition [2] - The upcoming acquisition of the third-largest beauty service brand, Siyuanli, will further consolidate the top three brands under Meili Tianyuan, expanding its store network to over 734 locations [2] Group 2: Strategic Initiatives - The company is focusing on the "self-consumption" upgrade trend among women in high-tier cities, effectively driving same-store revenue growth [3] - Meili Tianyuan plans to implement three major strategic initiatives: Super Brand, Super Chain, and Super Digitalization, aiming to redefine high-end beauty services and reshape industry value [3] - The company will continue to pursue a dual-driven growth strategy of "internal growth + external acquisitions," enhancing its "dual beauty + dual health" business model to create sustainable value for customers, shareholders, employees, and partners [3]

Core Viewpoint - Meili Tianyuan Medical Health (02373.HK) has announced a positive profit forecast for 2025, expecting revenue of at least 3 billion yuan, a year-on-year increase of no less than 16%, and a net profit of at least 3.4 billion yuan, reflecting strong resilience and growth potential amid economic fluctuations [1][3]. Group 1: Revenue and Profit Forecast - The company anticipates a revenue of no less than 3 billion yuan for 2025, representing a growth of at least 16% compared to 2024 [1]. - Adjusted net profit is expected to be no less than 3.8 billion yuan, indicating a year-on-year growth of at least 40% [1]. - Net profit is projected to be no less than 3.4 billion yuan, with a year-on-year increase of at least 34% [1]. Group 2: Strategic Expansion - The company is accelerating its external expansion through a dual growth strategy of "internal growth + external acquisitions," having successfully acquired the second-largest brand in China's beauty industry, Nairui'er, in 2024 [1]. - The integration of Nairui'er into Meili Tianyuan's brand matrix has significantly enhanced market share and business penetration in key areas of the Greater Bay Area [1]. - The acquisition has led to a strategic upgrade of the business model to a "dual beauty + dual healthcare" ecosystem, with Nairui'er’s adjusted net profit margin increasing from 6.5% before acquisition to 10.4% post-acquisition [1]. Group 3: Internal Growth and Market Position - Meili Tianyuan is capitalizing on the trend of "self-consumption" among women in high-tier cities, driving same-store revenue growth despite market challenges [3]. - The company is enhancing its medical business capabilities, with high-margin medical business revenue steadily increasing in 2025 [3]. - The store network has expanded to over 734 locations, capturing a significant market share in 20 first-tier and new first-tier cities [3]. Group 4: Future Strategies - The company will continue to implement its dual growth strategy of "internal growth + external acquisitions" and deepen the "dual beauty + dual healthcare" business model [5]. - A capital market value enhancement plan is set to be executed, aiming to create sustainable win-win outcomes for customers, shareholders, employees, and partners [5].

Core Viewpoint - Meili Tianyuan Healthcare (02373) expects to achieve a revenue of no less than RMB 3 billion in 2025, representing a growth of at least 16% compared to the same period in 2024, and an adjusted net profit of no less than RMB 380 million, reflecting a growth of at least 40% year-on-year [1] Group 1: Financial Projections - The company anticipates a net profit of no less than RMB 340 million in 2025, which is an increase of at least 34% compared to 2024 [1] - Revenue target for 2025 is set at no less than RMB 3 billion, indicating a growth of at least 16% from 2024 [1] - Adjusted net profit is projected to be no less than RMB 380 million, marking a growth of at least 40% year-on-year [1] Group 2: Reasons for Performance Improvement - Accelerated external expansion is a key driver, highlighted by the acquisition of the second-ranked brand in China's beauty industry, Nairui'er, which enhances market share and boosts revenue and profit [1] - Strong organic growth is noted, driven by an increase in brand momentum and customer numbers, leading to higher internal revenue growth and an increased proportion of high-margin medical business revenue [1] - The company emphasizes a dual strategy of "organic growth + external acquisitions" and aims to deepen its "dual beauty + dual healthcare" business model [1]

Core Viewpoint - The company anticipates achieving a revenue of no less than RMB 3 billion by 2025, representing a growth of at least 16% compared to the same period in 2024, alongside adjusted net profits of no less than RMB 3.8 billion, reflecting a growth of at least 40% [1] Group 1: Financial Projections - Expected revenue for 2025 is at least RMB 3 billion, a growth of no less than 16% from 2024 [1] - Adjusted net profit is projected to be no less than RMB 3.8 billion, indicating a growth of at least 40% compared to 2024 [1] - Net profit is anticipated to be no less than RMB 3.4 billion, with a growth of at least 34% from 2024 [1] Group 2: Reasons for Performance Improvement - Accelerated external expansion is a key driver, highlighted by the acquisition of the second-ranked brand in China's beauty industry, Nairui'er, which enhances market share and boosts revenue and profit [1] - Strong internal growth is noted, with an increase in brand momentum and customer numbers driving organic revenue growth, alongside a higher proportion of high-margin medical business revenue [1] - The company emphasizes a dual strategy of "internal growth + external acquisition" and aims to deepen its "dual beauty + dual healthcare" business model [1]

Core Viewpoint - The report from First Shanghai highlights that Meili Tianyuan Medical Health (02373) is enhancing its operational and integration capabilities through a dual approach of "internal growth + external expansion," with a target price of HKD 43.7 and an initial buy rating [1]. Group 1: Business Model and Ecosystem - Meili Tianyuan has established a "Double Beauty + Double Health" collaborative business model, creating a comprehensive beauty and health ecosystem that includes brands like Meili Tianyuan, Nairui'er, Xiuker, and Yanyuan, covering a full lifecycle of services from high-end beauty to health management [2]. - The core services focus on "lifestyle beauty + medical beauty + sub-health management," guiding customers from lifestyle beauty to high-value medical and health services, thus achieving comprehensive lifecycle management [2]. Group 2: Growth Strategy - The company employs a dual strategy of "internal growth + external expansion" to enhance operational and integration capabilities, utilizing 38 self-developed systems for refined operations, maintaining a customer repurchase rate above 80%, and keeping customer acquisition costs below 2% [3]. - On the external front, the company has made strategic acquisitions of Nairui'er and Siyanli, leveraging strong cash flow to significantly increase membership scale and net profit margins, showcasing strong synergy and integration capabilities [3]. Group 3: Industry Trends - Meili Tianyuan is positioned to lead the transformation of the beauty industry, which is trending towards branding, chain operations, and digitalization, by leveraging its multi-brand strategy, nationwide store network, and advanced digital systems [4]. - The company aims to transition the industry from a fragmented state to a more consolidated and robust structure, enhancing customer value through its "Double Beauty + Double Health" ecosystem [4]. Group 4: Financial Performance - In the first half of 2025, the company reported strong performance with direct store traffic reaching 920,000, a year-on-year increase of 47.8%, and active members rising to 120,000, up 46.5% [5]. - Revenue reached RMB 1,459 million, reflecting a year-on-year growth of 28.2%, while adjusted net profit was RMB 191 million, achieving a record high adjusted net profit margin of 13.1%, demonstrating exceptional profitability resilience amid macro pressures [5]. Group 5: Profit Forecast - The company has significant growth potential driven by both internal growth and acquisition capabilities, with its true growth boundary dependent on management capabilities [6]. - Using a discount rate of 10% and a perpetual growth rate of 3%, the estimated fair value of the company is HKD 10.3 billion, with a target price of HKD 43.7, indicating a potential upside of 65.4% from the previous closing price, corresponding to PE ratios of 29.8 and 24.5 for 2025 and 2026 respectively, thus receiving a buy rating [6].

Core Viewpoint - The company maintains its profit forecast for 2025-2026, with the current stock price corresponding to a P/E ratio of 25/22x for those years, and has raised its target price by 5% to HKD 42, indicating a 25% upside potential [1] Group 1: Company Current Situation - On October 15, the company announced a strategic acquisition of 100% equity in Siyuanli for a consideration of HKD 1.25 billion, with a transaction valuation of 14.8x P/E (LTM). The payment structure includes HKD 330 million in cash, HKD 510 million in acquisition loans, and HKD 410 million in share payments, with shares issued at HKD 28.71 per share, representing 6.70% of the total issued shares, subject to a lock-up period of 6 months to 1 year. The transaction is expected to be completed by December 2025, after which Siyuanli will be consolidated into the company's financial statements [2] Group 2: Market Position Enhancement - The acquisition of Siyuanli, the third-largest beauty service brand in China, is expected to further enhance market share. According to Sullivan, Siyuanli's projected revenue and net profit for 2024 are HKD 850 million and HKD 80 million, respectively, with a net profit margin of 9.6%. As of the first half of 2025, Siyuanli operates 163 beauty service stores and 19 medical beauty clinics across 48 cities in China, with over 90% of its revenue coming from the top 20 first-tier and new first-tier cities. Post-acquisition, the combined entity will cover 42% of high-end commercial properties in these cities, expanding its market share in high-end beauty services and increasing the number of active members by 44% compared to 2024 [3][5] Group 3: Operational Efficiency and Synergy - The company has over 30 successful acquisition integration experiences over its 32 years in the industry, indicating its capability to systematically provide mature medical beauty and sub-health services to Siyuanli. This will cover the full cycle of customer beauty and health needs, optimizing operational efficiency and profitability through refined customer operations, digital transformation, and supply chain integration [4] Group 4: Strengthening Leadership Position - The company has strengthened its leadership position in the beauty and health industry through the acquisitions of the second brand Nairui and the third brand Siyuanli within 2024-2025. This strategy enhances the "dual beauty + dual health" business model by providing a larger member flow, denser high-end commercial networks, and stronger medical service capabilities, indicating a broad growth potential for the company [5]

Core Viewpoint - The report from CICC maintains the profit forecast for Meili Tianyuan Medical Health (02373) for 2025-2026, with the current stock price corresponding to a P/E ratio of 25/22x for those years. The target price is raised by 5% to HKD 42, indicating a 25% upside potential [1]. Company Status - On October 15, the company announced a strategic acquisition of 100% equity in Siyuanli for a consideration of RMB 1.25 billion, with a transaction valuation of 14.8x P/E (LTM). The payment structure includes RMB 330 million in cash, RMB 510 million in acquisition loans, and RMB 410 million in share payments, with shares issued at HKD 28.71 each, representing 6.70% of the total issued shares, subject to a lock-up period of 6 months to 1 year. The transaction is expected to be completed by December 2025, after which Siyuanli will be consolidated into the company's financial statements [2]. Market Position Enhancement - Siyuanli is recognized as the third-largest beauty service brand in China for 2024, with projected revenues and net profits of RMB 850 million and RMB 80 million, respectively, and a net profit margin of 9.6%. The company operates 163 beauty service stores and 19 medical beauty clinics across 48 cities in China, with over 90% of its revenue coming from the top 20 first-tier and new first-tier cities. Post-acquisition, the combined entity will cover 42% of high-end commercial properties in these cities, enhancing market share in the high-end beauty service sector [3]. Operational Efficiency and Synergy - With over 30 successful acquisition integration experiences over 32 years, the company is expected to systematically provide mature medical beauty and sub-health services to Siyuanli, addressing the full cycle of customer beauty and health needs. The focus will be on optimizing operational efficiency and profitability through refined customer operations, digital transformation, and supply chain integration [4]. Strengthening Market Leadership - The company has acquired the second and third brands in the beauty service industry, Nairui and Siyuanli, respectively, within 2024-2025. This strategy enhances the "Double Beauty + Double Health" business model by increasing member traffic, expanding high-end commercial networks, and strengthening medical service capabilities, further solidifying its leadership position in the beauty and health industry [5].

Investment Rating - The report maintains a "Buy" rating for the company [1][8]. Core Insights - The company achieved record high revenue and profit, driven by significant growth in its sub-healthcare segment [5]. - The company's revenue for H1 2025 reached 1.459 billion RMB, a year-on-year increase of 28.2%, with a net profit of 171 million RMB, up 35.5% year-on-year [5]. - The "internal + external" strategy is expected to continue driving growth, with projected revenues of 3 billion RMB in 2025, 3.4 billion RMB in 2026, and 3.7 billion RMB in 2027 [5]. Financial Performance - The company reported a gross margin of 49.3% for H1 2025, an increase of 2.3 percentage points year-on-year [5]. - The operating cash flow for H1 2025 was 410 million RMB, reflecting an 84.4% increase year-on-year [5]. - As of June 30, 2025, the company had cash and cash equivalents totaling 2 billion RMB, a 27.5% increase year-on-year [5]. Business Segments - The beauty and wellness services segment generated revenue of 807 million RMB in H1 2025, a year-on-year increase of 29.6% [5]. - The medical beauty segment reported revenue of 499 million RMB, up 13.0% year-on-year, driven by increased patient visits [5]. - The sub-healthcare services segment saw remarkable growth, with revenue reaching 154 million RMB, a 107.8% increase year-on-year [5]. Membership Growth - The company experienced a 46.5% year-on-year increase in active members, reaching 120,000 members [5]. - The number of visitors to direct-operated stores exceeded 920,000 in H1 2025, representing a 47.8% increase year-on-year [5]. Future Projections - The company forecasts revenue growth of 18% in 2025, followed by 10% in 2026 and 9% in 2027 [5]. - The projected net profit for 2025 is 300 million RMB, with expected growth rates of 34% in 2025, 15% in 2026, and 15% in 2027 [5].

Core Viewpoint - The company reported strong performance in 1H25, exceeding previous forecasts and expectations, driven by scale effects and operational efficiency improvements [1][2]. Financial Performance - Revenue for 1H25 reached 1.46 billion yuan, a year-on-year increase of 28.2% - Net profit attributable to shareholders was 160 million yuan, up 34.9% - Adjusted net profit was 190 million yuan, reflecting a 37.8% increase [1] - Gross margin improved by 2.4 percentage points to 49.3%, attributed to scale effects reducing procurement costs and diluting fixed costs [2] - Adjusted net profit margin reached a historical high of 13.1%, up 0.9 percentage points year-on-year [2] Business Segments - Beauty and health services generated 810 million yuan in revenue, a 29.6% increase, with direct store traffic up 48.6% to 850,000 visits [1] - Medical beauty services revenue was 500 million yuan, a 13.0% increase, with active membership rising 27.6% to 24,000 [1] - Sub-health medical services saw revenue growth of 107.8% to 150 million yuan, with active members increasing 93.4% to 7,014 [1] Growth Strategy - The company is expanding its store network, adding 69 direct/franchise beauty and health service stores, 3 medical beauty stores, and 2 sub-health stores in 1H25 [1] - The company is focusing on enhancing operational efficiency and exploring acquisition opportunities to increase market share [3] - Recent changes in shareholder structure, including the entry of quality medical capital, are expected to support long-term growth [3] Valuation and Outlook - The company maintains its profit forecasts for 2025-2026, with current stock price corresponding to 25/21x P/E for those years [3] - Target price has been raised by 8% to 40 HKD, indicating a 21% upside potential based on the company's strong business model and growth opportunities [3]